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The  N-glycosylation of antibodies for their use as drugs 
Glycosylation of antibodies is something essential to avoid the development of an immune 
response. Moreover, it is expected that more than a  30% of the licensed drugs during the next 
decade will be antibodies, so the reduction of their production costs is crucial in a competitive 
market.  
Current antibodies production methods 
1. Engineered CHO cells:  They have incorporated the genes of the human  
N-acetylglucosaminyltransferase-III and alpha-2,6-sialyltransferase-I . 
2. Picchia pastoris: Glycofi (Lebanon, USA) obtained a humanized strain of P. pastoris which 
produced glycoproteins with the N-glycosylation of humans using synthetic biology tools.  
Goals 
1. To obtain a recombinant strain of S. cerevisiae that produces humanized N-glycosylated 
proteins. 
2. To compare the results between the strain obtained by directed genetic engineering and the 
strain obtained by synthetic biology. 
3. To discuss which improvements could be made to obtain a better humanized strain of  
S. cerevisiae. 
An strain producing glycoproteins with Man5GluNAc2 was achieved. The process consisted of two 
steps:  
1. Those genes of the yeast implied in the hyper-mannosylation of the glycoprotein in the Golgi 
were deleted (ΔOCH1, ΔMNN1). As a result, the yeast could not modify Man8GluNAc2.  
2. The gene α-1,2-mannosidase of Aspergillus saitoi was added with a plasmid. This enzyme 
hydrolyzes the mannoses of Man8GluNAc2. Its sequence was fused to HDEL sequence for the 
retention of the enzyme into the endoplasmic reticulum (ER).  
Result: Heterogeneous product and growth deficiencies.  
Directed genetic engineering 
Strain’s 
name 
Gene 
Source of the 
gene 
Promoter Product 
Amélie α-1,2-mannosidase I C. elegans pGAP Man5GlcNAc2 
Arielle N-acetylglucosaminyltransferase I Human pGAP GlcNacMan5GlcNAc2 
Anaïs Mannosidase II Mice PGK GlcNacMan3GlcNAc2 
Alice N-acetylglucosaminyltransferase II Human PMAI GlcNac2Man3GlcNAc2 
Athena Β-1,4-galactosyltransferase I Human CaMV Gal2GlcNac2Man3GlcNAc2 
Aeron α-2,3-sialiltransferase Human SV40 Sia2Gal2GlcNAc2Man3GlcNAc2 
Glycode SAS (Uzerche, France) developed a recombinant strain of S. cerevisiae which could 
produce the oligosaccharide of interest with more than a 75% of homogeneity.  It consisted in 
using integrative vectors which were  specifically integrated into auxotrophic cassettes of the 
genome of S. cerevisiae. It was a step by step optimization process which was based on a high 
throughput screening of the results obtained with multiple combinations of ER and Golgi 
localization sequences and different glycosyl-enzymes genes. The screening consisted of two 
steps: Production of an heterologous protein in a microfermenter and MALDI-TOF analysis. 
Each strain had a different name and it was obtained after the performance of one cycle as it is shown in the figure above.  
Endogenous N-glycosyaltion pathway in humans and yeasts 
Genetic engineering 
1. The strain obtained using directed genetic engineering achieved just the first steps of a modified N-glycosylation 
pathway. Moreover, the product was heterogeneous and the  growth of the recombinant strain was diminished.  
2. The recombinant strain obtained using the tools of synthetic biology achieved the desired product with higher 
homogeneity (more than a 75%). However, the titers of humanized IgG achieved with this cell culture have not been 
reported and Glycode SAS is no longer active. 
3. Research has focused on improving the mainstream methods for the production of humanized antibodies (improved 
CHO cells). 
4. The knowledge of other N-glycosylation pathways and the implications of the modification of the endogenous 
glycoproteins or S. cerevisiae and perseverance using synthetic biology tools could lead to obtaining a recombinant 
strain which gets the desired product in a competitive level.  
IgG are N-glycosylated at the position Asn297. The 
oligosaccharide always contains, at least, the blue 
heptasaccharide, but further modifications could 
take place to change the antibody activity. 
Terminal sialic acids have shown increased ADCC 
(antibody dependent cellular cytotoxicity) and, for 
this reason, they are an interesting option for the 
synthesis of drugs against autoimmune diseases 
and inflammatory disorders.  
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